Barclays
IDIX

Barclays’s IDENIX PHARMACEUTICALS INC IDIX Stock Holding History

Barclays’s Portfolio IDIX Stock Details IDIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-603,500
Closed -$14.5M – 8064
2014
Q2 		$14.5M Buy
603,500
+577,500
+2,221% +$6.02M 0.02% 907
2014
Q1 		$156K Buy
26,000
+5,400
+26% +$37.7K ﹤0.01% 5039
2013
Q4 		$103K Sell
20,600
-16,600
-45% -$76.8K ﹤0.01% 5621
2013
Q3 		$186K Sell
37,200
-14,500
-28% -$63.5K ﹤0.01% 5110
2013
Q2 		$187K Buy
+51,700
New +$211K ﹤0.01% 5242

Barclays's IDIX Position: Q3 2014 in Review

Barclays sold out of IDENIX PHARMACEUTICALS INC (IDIX) in Q3 2014, closing a stake of 1,402,950 shares — an estimated $33.7M sold.

Barclays first reported a position in IDIX in Q2 2013 and held it in 5 quarters. The position peaked at $33.7M in Q2 2014. 0 funds tracked by Wall St. Rank hold IDIX as of Q3 2014.

  • Barclays reported no remaining IDENIX PHARMACEUTICALS INC position as of Q3 2014 after selling out during the quarter.
  • Barclays sold 1,402,950 IDENIX PHARMACEUTICALS INC shares in Q3 2014, an estimated $33.7M.
  • Barclays first reported a position in IDENIX PHARMACEUTICALS INC in Q2 2013 and held it in 5 quarters.
  • Barclays's IDENIX PHARMACEUTICALS INC position peaked at $33.7M in Q2 2014.
  • 0 funds tracked by Wall St. Rank held IDENIX PHARMACEUTICALS INC as of Q3 2014.

Based on Barclays's 13F filing for Q3 2014, filed 14 Nov 2014.